Metastatic Prostate Cancer - Pipeline Review, H1 2014


#196452

78pages

Global Markets Direct

$ 2000

In Stock

Metastatic Prostate Cancer Pipeline Review, H1 2014, provides an overview of the Metastatic Prostate Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Prostate Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Metastatic Prostate Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Metastatic Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Metastatic Prostate Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Metastatic Prostate Cancer - Overview 9
Pipeline Products for Metastatic Prostate Cancer - Comparative Analysis 10
Metastatic Prostate Cancer - Therapeutics under Development by Companies 11
Metastatic Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 13
Metastatic Prostate Cancer - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Metastatic Prostate Cancer - Products under Development by Companies 17
Metastatic Prostate Cancer - Products under Investigation by Universities/Institutes 18
Metastatic Prostate Cancer - Companies Involved in Therapeutics Development 19
Sanofi 19
Progenics Pharmaceuticals, Inc. 20
MEI Pharma, Inc. 21
OXiGENE, Inc. 22
Colby Pharmaceutical Company 23
Camurus AB 24
Actinium Pharmaceuticals, Inc. 25
Fountain Biopharma Inc. 26
Agonox 27
AbbVie Inc. 28
Metastatic Prostate Cancer - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Mechanism of Action 34
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
cabazitaxel - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
pracinostat - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
leuprolide acetate - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
LU-901 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
veliparib - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Engineered Autologous T Cells + [cyclophosphamide] - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
MEDI-6469 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CPC-410 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Actimab-P - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Peptide to Inhibit MT1 MMP for Autoimmune Disorders, Inflammation and Oncology - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
MIP-1095 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
FB-704A - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Ceramide Analogs - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
KGP-94 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Vaccine For Oncolytic Newcastle Disease Virus - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Glutathione Disulfide Liposomal - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Metastatic Prostate Cancer - Recent Pipeline Updates 61
Metastatic Prostate Cancer - Dormant Projects 66
Metastatic Prostate Cancer - Discontinued Products 67
Metastatic Prostate Cancer - Product Development Milestones 68
Featured News & Press Releases 68
Apr 07, 2014: Bavarian Nordic Presents Combination Immunotherapy Data of PROSTVAC plus Ipilimumab at the AACR Annual Meeting 2014 68
Apr 03, 2014: Astellas Announces European Regulatory Submission For XTANDI Capsules For Chemotherapy-Naive Metastatic Prostate Cancer 68
Apr 02, 2014: Bayer Initiates Phase 3 Trial of Xofigo (radium Ra 223 dichloride) Injection in Combination with Abiraterone Acetate for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Bone Predominant Metastatic Castration-Resistant Prostate Cancer 69
Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference 70
Feb 06, 2014: ZYTIGA Now Reimbursed in Qubec for Use Prior to Chemotherapy in Men with Metastatic Prostate Cancer 71
Jan 30, 2014: Progenics Pharmaceuticals Presents Positive Data From a Phase 2 Trial of PSMA ADC in Patients With Chemotherapy Experienced Metastatic Castrate Resistant Prostate Cancer 71
Jan 28, 2014: Medivation and Astellas Announce Final Results From the Phase 3 PREVAIL Trial of Enzalutamide in Men With Metastatic Prostate Cancer Progressing on Androgen Deprivation Therapy 72
Dec 19, 2013: Data From PREVAIL Trial of Enzalutamide in Chemotherapy-Naive Metastatic Prostate Cancer to Be Presented in Late-Breaking Session at ASCO GU Symposium 74
Nov 21, 2013: ZYTIGA Now Available for Men with Metastatic Prostate Cancer in British Columbia Prior to Chemotherapy 75
Jun 28, 2013: Dendreon Receives Positive Opinion for PROVENGE in the European Union 75

Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 78
Disclaimer 78

Number of Products under Development for Metastatic Prostate Cancer, H1 2014 9
Number of Products under Development for Metastatic Prostate Cancer - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Metastatic Prostate Cancer - Pipeline by Sanofi, H1 2014 19
Metastatic Prostate Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H1 2014 20
Metastatic Prostate Cancer - Pipeline by MEI Pharma, Inc., H1 2014 21
Metastatic Prostate Cancer - Pipeline by OXiGENE, Inc., H1 2014 22
Metastatic Prostate Cancer - Pipeline by Colby Pharmaceutical Company, H1 2014 23
Metastatic Prostate Cancer - Pipeline by Camurus AB, H1 2014 24
Metastatic Prostate Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2014 25
Metastatic Prostate Cancer - Pipeline by Fountain Biopharma Inc., H1 2014 26
Metastatic Prostate Cancer - Pipeline by Agonox, H1 2014 27
Metastatic Prostate Cancer - Pipeline by AbbVie Inc., H1 2014 28
Assessment by Monotherapy Products, H1 2014 29
Assessment by Combination Products, H1 2014 30
Number of Products by Stage and Target, H1 2014 33
Number of Products by Stage and Mechanism of Action, H1 2014 36
Number of Products by Stage and Route of Administration, H1 2014 38
Number of Products by Stage and Molecule Type, H1 2014 40
Metastatic Prostate Cancer Therapeutics - Recent Pipeline Updates, H1 2014 61
Metastatic Prostate Cancer - Dormant Projects, H1 2014 66
Metastatic Prostate Cancer - Discontinued Products, H1 2014 67

Number of Products under Development for Metastatic Prostate Cancer, H1 2014 9
Number of Products under Development for Metastatic Prostate Cancer - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 29
Number of Products by Top 10 Target, H1 2014 31
Number of Products by Stage and Top 10 Target, H1 2014 32
Number of Products by Top 10 Mechanism of Action, H1 2014 34
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 35
Number of Products by Top 10 Route of Administration, H1 2014 37
Number of Products by Stage and Top 10 Route of Administration, H1 2014 38
Number of Products by Top 10 Molecule Type, H1 2014 39
Number of Products by Stage and Top 10 Molecule Type, H1 2014 40